Sotera Health (SHC)

Healthcare · Diagnostics & Research
$18.06 +1.29% on the day Market cap $5.1B 52-week range $13.09 to $19.85 Prices as of Oct 11, 2026

What the price implies

A reverse DCF: instead of guessing a fair value, it asks what growth today's price already assumes. How it works.

Free cash flow growth the price needs
12% a year for 10 years

At a market value of $5.1B, Sotera Health's free cash flow of $149M (fiscal 2025) would need to grow about 12% a year for the stock to be worth today's price. That is faster than the company has grown its free cash flow over the last 6 years.

Assumes a 9% discount rate and 3% growth after year 10, on free cash flow (operating cash flow minus capital spending) from Sotera Health's SEC filings. Change any assumption, or model revenue and margins instead, in the Modeling tab, or try your own numbers in the reverse DCF calculator.

Implied by the price11.9% a year
Free cash flow, last 6 years8.4% a year
Revenue, same period6.9% a year
Price to free cash flow34.0x

Fundamental grade

C

Five factors scored 1 to 9 from SHC's latest numbers, weighted into one grade. It describes the business, not whether the stock is a buy.

Valuation4
Profitability6
Growth7
Financial health4
Cash efficiency7

Results from SEC filings

Fiscal years, from Sotera Health's 10-K filings. Ten years of the full income statement, balance sheet and cash flow.

Fiscal year20212022202320242025
Revenue$931M$1.0B$1.0B$1.1B$1.2B
Net income$117M-$234M$51M$44M$78M
Free cash flow$179M$96M-$363M$45M$149M
EPS (diluted)$0.41-$0.83$0.18$0.16$0.27
Operating margin27.6%24.7%26.4%27.0%—

Where the revenue comes from

Revenue by segments, fiscal 2025. Every breakdown, year by year.

Sterigenics$756M65%
Nelson Labs$220M19%
Nordion$188M16%

Superinvestors who own SHC

From each investor's latest 13F filing (what a 13F shows). 4 of the investors we track hold it.

InvestorLast quarterValue% of portfolioQuarter
Cliff Asness
AQR Capital Management
Added $186M0.06%Q2 2026
Joel Greenblatt
Gotham Asset Management
Added $39M0.09%Q2 2026
David Einhorn
Greenlight Capital
Held $6M0.28%Q4 2023
Charles Brandes
Brandes Investment Partners, LP
Added $3M0.02%Q2 2026

Insider buying

Open-market purchases by Sotera Health's executives and directors in the last 12 months, from SEC Form 4 filings. What insider buying tells you.

No open-market insider purchases of SHC in the last 12 months. Most insider activity is selling and option exercises, which aren't shown here.

Get an alert at your buy price

Pick the price you'd be interested at. We'll email you when SHC trades at or below it.

$

New accounts get 7 days of Pro, price alerts included. No card needed.

In the full deep dive

DCF fair value per share
Yearly return (IRR) at today's price
Growth implied by revenue and margins
15+ years of statements and quarters

Questions

What growth does Sotera Health's stock price imply?

At a market value of $5.1B, Sotera Health would need its free cash flow to grow about 12% a year for 10 years (discounted at 9%, 3% growth after that) to be worth today's price. Over the last 6 years its free cash flow grew 8% a year.

Are Sotera Health insiders buying the stock?

No open-market insider purchases of SHC in the last 12 months, according to SEC Form 4 filings.

Which superinvestors own Sotera Health?

4 of the superinvestors Investingly tracks hold SHC in their latest 13F, including Cliff Asness, Joel Greenblatt, David Einhorn.

Prices and ratios as of Oct 11, 2026; statements from SEC filings. Information only, not investment advice. Superinvestor holdings come from 13F filings, which are filed up to 45 days after each quarter ends.